Ipsen (Rights to Satoreotide) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Ipsen (Rights to Satoreotide) General Information
Description
Rights to an early clinical development proprietary peptide derivative that binds to somatostatin receptor 2 (SSTR2), which is overexpressed in neuroendocrine tumors and some aggressive cancers.
Contact Information
Corporate Office
- Boulogne Billancourt
- France
Corporate Office
- Boulogne Billancourt
- France
Ipsen (Rights to Satoreotide) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Ipsen (Rights to Satoreotide) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Ipsen (Rights to Satoreotide) FAQs
-
Where is Ipsen (Rights to Satoreotide) headquartered?
Ipsen (Rights to Satoreotide) is headquartered in Boulogne Billancourt, France.
-
What industry is Ipsen (Rights to Satoreotide) in?
Ipsen (Rights to Satoreotide)’s primary industry is Buildings and Property.
-
Is Ipsen (Rights to Satoreotide) a private or public company?
Ipsen (Rights to Satoreotide) is a Private company.
-
What is Ipsen (Rights to Satoreotide)’s current revenue?
The current revenue for Ipsen (Rights to Satoreotide) is .
-
Who are Ipsen (Rights to Satoreotide)’s investors?
Ipsen has invested in Ipsen (Rights to Satoreotide).
-
When was Ipsen (Rights to Satoreotide) acquired?
Ipsen (Rights to Satoreotide) was acquired on 22-Oct-2021.
-
Who acquired Ipsen (Rights to Satoreotide)?
Ipsen (Rights to Satoreotide) was acquired by Ariceum.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process